Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD
27.20
-2.03 (-6.94%)
At close: Jul 15, 2025, 4:00 PM
27.40
+0.20 (0.74%)
After-hours: Jul 15, 2025, 5:42 PM EDT
-6.94%
Market Cap 2.57B
Revenue (ttm) 590.69M
Net Income (ttm) -549.58M
Shares Out 94.38M
EPS (ttm) -5.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,766,512
Open 29.34
Previous Close 29.23
Day's Range 26.85 - 29.36
52-Week Range 26.85 - 60.37
Beta 0.26
Analysts Strong Buy
Price Target 87.40 (+221.32%)
Earnings Date Jul 31, 2025

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 1,294
Stock Exchange NASDAQ
Ticker Symbol RARE
Full Company Profile

Financial Performance

In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.

Financial Statements

Analyst Summary

According to 15 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $87.4, which is an increase of 221.32% from the latest price.

Price Target
$87.4
(221.32% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.

Other symbols: AAPL
1 day ago - Benzinga

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder

The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat a rare genetic disorder, the company said on Friday.

4 days ago - Reuters

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable

4 days ago - GlobeNewsWire

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.

5 days ago - Benzinga

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.

Other symbols: MEI
5 days ago - Benzinga

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Data from Orbit and Cosmic studies expected around the end of the year Data from Orbit and Cosmic studies expected around the end of the year

6 days ago - GlobeNewsWire

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27...

18 days ago - GlobeNewsWire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...

25 days ago - GlobeNewsWire

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

6 weeks ago - GlobeNewsWire

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. T...

2 months ago - GlobeNewsWire

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...

2 months ago - GlobeNewsWire

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

2 months ago - Seeking Alpha

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

First quarter total revenue of $139 million,  Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million

2 months ago - GlobeNewsWire

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser...

2 months ago - GlobeNewsWire

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from ...

3 months ago - Seeking Alpha

Ultragenyx to Participate at Investor Conferences in March

NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

5 months ago - GlobeNewsWire

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO ...

5 months ago - Seeking Alpha

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million

5 months ago - GlobeNewsWire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

5 months ago - GlobeNewsWire

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc RARE.

6 months ago - Benzinga

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance,  including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 ...

6 months ago - GlobeNewsWire

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

6 months ago - GlobeNewsWire

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

First and only medicine approved in the EU for paediatric patients aged 6-months to 5 years old with HoFH, an ultrarare, inherited form of high cholesterol First and only medicine approved in the EU f...

6 months ago - GlobeNewsWire

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ul...

7 months ago - GlobeNewsWire